Cardiovascular Video Recap—February 12, 2026

Welcome to the latest edition of Cardiovascular Updates, covering the latest breakthroughs. Brought to you by LucidQuest.

Milestone Pharmaceuticals signaled mid-February U.S. commercialization of etripamil, brand name Cardamyst, a home-use nasal spray for acute conversion of paroxysmal supraventricular tachycardia in adults following FDA approval in December 2025, with payer engagement and copay support planned. This could shift some PSVT episodes from the emergency department to at-home care, depending on access and coverage.

Allegheny Health Network opened Pennsylvania’s first South Asian Heart Clinic, a prevention-focused program offering advanced biomarkers including Lp(a) and ApoB, genetics, coronary calcium scoring, metabolic assessment, and culturally specific counseling, with collaboration across cardiology and endocrinology

AngioDynamics convened a Cardiovascular Scientific Forum in Fort Lauderdale, underscoring evidence generation and reimbursement planning across venous thromboembolism, blood management, and structural infection, with IDEs active for Apex-Return in intermediate-risk pulmonary embolism and Pave in right-sided infective endocarditis, plus a modified AlphaVac F1885 with expanded 510(k) clearance

Bayer reported that in Oceanic-Stroke, a Phase 3 trial of more than 12,300 patients with non-cardioembolic ischemic stroke or high-risk TIA on antiplatelets, asundexian 50 mg reduced recurrent stroke without increasing major bleeding, with full data presented at the International Stroke Conference and U.S. fast-track designation for secondary prevention

The AHA and ASA issued an updated early acute ischemic stroke guideline, replacing 2018 recommendations, endorsing alteplase or tenecteplase within 4.5 hours for eligible disabling deficits without advanced imaging selection, expanding endovascular therapy, including basilar artery occlusion within 24 hours when NIHSS is 10 or higher, and adding pediatric and mobile stroke unit guidance

Abbott reported early Veritas data for the Amulet 360 left atrial appendage occlusion system, with 93.9 percent complete closure at 45 days, high implant success, and low early complications across 400 patients at 34 sites in the U.S., Canada, and Europe, with results presented at the AF Symposium and published in JACC: EP

The TricValve bicaval valve system received EU MDR Class III certification for severe tricuspid regurgitation with caval reflux, supporting EU availability and international expansion, while the U.S. TRICAV II pivotal remains authorized under an IDE from December 2025

Brainomix introduced next-generation stroke AI at the International Stroke Conference in New Orleans, adding automated net water uptake from non-contrast CT to the Brainomix 360 platform alongside ischemic core and e-Aspects, with regulatory-cleared NWU output intended to support early injury assessment and transfer decisions, and multiple abstracts highlighted

Stay ahead in cardiovascular research! Like, share, and subscribe for weekly updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!